ArticleScientific reports2025
Development and validation of an LC-MS/MS method for quantitative determination of LXT-101 sustained-release suspension, a novel drug in treating prostate cancer, in beagle plasma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics of LXT-101 sustained-release suspension, an anti-prostate cancer polypeptide, were studied on beagle dogs using a high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Samples were prepared by the protein precipitation, evaporation and reconstitution. Chromatographic separation was performed using a Hypersil GOLD C18 column (50 mm × 2.1 mm, I.D. 5 μm). The mobile phase consisted of acetonitrile, water and formic acid (20:80:0.1, v/v/v) at a flow rate of 0.3 mL/min. The acquisition was carried out in selected reaction monitoring (SRM). The method was validated in terms of selectivity, linearity, precision and accuracy, extraction recovery and matrix effect, and stability. It showed good linearity over the range of 2-600 ng/mL (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.